The text argues that the U.S. department of Justice and DEA\u2019s decision to move marijuana products from Schedule I to Schedule III is misguided. It claims marijuana should not be reclassified as \u201cmoderate\/low abuse potential\u201d because it is widely used and associated with substantial rates of cannabis use disorder, including among young people. <\/p>\n

it also argues that the change would treat state-licensed medical products like approved prescription medicines, despite not matching the stringent federal requirements applied to other Schedule III drugs (FDA approval, DEA-registered manufacturers\/distributors, and controlled prescribing standards). <\/p>\n

The article further contends that rescheduling was not genuinely necessary for medical research-as CBD and hemp-based products<\/a> are already regulated-and criticizes the perceived rush of the policy. it argues the real motive is financial, claiming Schedule III status would benefit the cannabis industry through large federal tax breaks, worsening the national addiction<\/a> and public-health situation. <\/p>\n